All lobbying filings

Williams and Jensen, PLLC

Williams and Jensen, PLLC filed a Q3 report for Pfizer on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Pfizer

As filed: WILLIAMS AND JENSEN, PLLC for PFIZER.

All filings by Williams and Jensen, PLLC · Everything Pfizer has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 4

CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
JOSHUA DAVID FENDRICK

Previously held: Staff Assistant, Legislative Correspondent, and Legislative Aide, Sen. Gary C. Peters; Economic Policy Adviser, Rep. Josh Gottheimer; Economic Policy Adviser, Sen. Gary C. Peters
ROBERT BUTORA

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Budget/Appropriations

Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.

Defense

Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.

Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Legislation and issues related to prior authorization. Issues related to TrumpRX.

Taxation/Internal Revenue Code

Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP.

Medicare/Medicaid

Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Issues related to China WRT the BINSA Bill.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.